Danny Zanardo - Anteris Technologies Commercial International

AMEUF Stock  USD 6.50  0.43  7.08%   

Executive

Mr. Danny Zanardo is Director of Sales of Admedus Ltd, formerly Allied Healthcare Group Ltd. He has over 20 years experience in the Australian healthcare sector via positions with multinational pharmaceutical companies, biopharmaceutical startup, and medical device companies. He has gained formal qualifications via a degree in applied science and has built upon this with post graduate business studies, and is currently working towards completing his MBA. During his career, he has developed networks and an intimate understanding of medical device and pharmaceutical commercial and clinical environments. He has a track record of sales, marketing and clinical teams in commercial projects, with new and existing medical technology, that have resulted in revenue growth. Danny has worked with Rousell Uclaf, Hoffman La Roche, and Actelion. He joined Allied Medical as a Regional Sales Manager in 2004 and became National Sales Manager in 2005.
Professional MarksMBA
Phone61 13 0055 0310
Webhttps://www.anteristech.com

Anteris Technologies Management Efficiency

The company has return on total asset (ROA) of (0.8433) % which means that it has lost $0.8433 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.5517) %, meaning that it generated substantial loss on money invested by shareholders. Anteris Technologies' management efficiency ratios could be used to measure how well Anteris Technologies manages its routine affairs as well as how well it operates its assets and liabilities.
Anteris Technologies has accumulated 4.07 M in total debt with debt to equity ratio (D/E) of 0.13, which may suggest the company is not taking enough advantage from borrowing. Anteris Technologies has a current ratio of 4.22, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Anteris Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, Anteris Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Anteris Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Anteris to invest in growth at high rates of return. When we think about Anteris Technologies' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 2 records

EXECUTIVE Age

Kevin WilliamsonTenon Medical
39
Deina WalshBone Biologics Corp
60
Anteris Technologies Ltd operates as a structural heart company. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia. Admedus operates under Medical Devices classification in the United States and is traded on OTC Exchange. Anteris Technologies [AMEUF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Anteris Technologies Leadership Team

Elected by the shareholders, the Anteris Technologies' board of directors comprises two types of representatives: Anteris Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anteris. The board's role is to monitor Anteris Technologies' management team and ensure that shareholders' interests are well served. Anteris Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anteris Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
AC FAA, Exec
Wayne Paterson, Non-Executive Independent Director
Matthew McDonnell, Chief Officer
David Denis, Chief Officer
Stephen Denaro, Independent Sec
Chris Olig, Bus Director
Danny Zanardo, Commercial International
MPH MD, Chief Board

Anteris Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Anteris Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Anteris Pink Sheet

Anteris Technologies financial ratios help investors to determine whether Anteris Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Anteris with respect to the benefits of owning Anteris Technologies security.